AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...

Transcend also saw significant improvements on secondary endpoints that assessed the rate of response, remission and loss of ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Cologuard is getting an upgrade after 10 years on the market, as Exact Sciences starts to roll out the new version of its ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...